The therapeutic community is exhibiting considerable excitement in Asenlix, a recently developed therapy designed to treat the symptoms of mood disorders. Unlike traditional antidepressants that primarily target on serotonin, Asenlix offers a unique mechanism of effect, potentially impacting various neurotransmitter networks involved in psychologic